Skip to main content

NUEVOS GENES IMPLICADOS EN LA FUNCION OXPHOS: DESARROLLO DE MODELOS EXPERIMENTALES PARA EL DIAGNOSTICO, ESTUDIO Y TRATAMIENTO DE LAS ENFERMEDADES MITOCONDRIALES

PID2019-110320RB-I00

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Call year 2019
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre UNIVERSIDAD AUTONOMA DE MADRID

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Multicentric Standardization of Protocols for the Diagnosis of Human Mitochondrial Respiratory Chain Defects

  • Buján, Núria
  • Morén, Constanza
  • García-García, Francesc J.
  • Blázquez, Alberto
  • Carnicer, Clara
  • Cortés, Ana Belén
  • Gónzalez, Cristina
  • López-Gallardo, Ester
  • Lozano, Ester
  • Moliner, Sonia
  • Gort, Laura
  • Tobías, Ester
  • Delmiro, Aitor
  • Martín, Miguel Ángel
  • Fernández-Moreno, Miguel Ángel
  • Ruiz-Pesini, Eduardo
  • Garcia-Arumí, Elena
  • Rodríguez-Aguilera, Juan Carlos
  • Garrabou, Glòria
The quantification of mitochondrial respiratory chain (MRC) enzymatic activities is essential for diagnosis of a wide range of mitochondrial diseases, ranging from inherited defects to secondary dysfunctions. MRC lesion is frequently linked to extended cell damage through the generation of proton leak or oxidative stress, threatening organ viability and patient health. However, the intrinsic challenge of a methodological setup and the high variability in measuring MRC enzymatic activities represents a major obstacle for comparative analysis amongst institutions. To improve experimental and statistical robustness, seven Spanish centers with extensive experience in mitochondrial research and diagnosis joined to standardize common protocols for spectrophotometric MRC enzymatic measurements using minimum amounts of sample. Herein, we present the detailed protocols, reference ranges, tips and troubleshooting methods for experimental and analytical setups in different sample preparations and tissues that will allow an international standardization of common protocols for the diagnosis of MRC defects. Methodological standardization is a crucial step to obtain comparable reference ranges and international standards for laboratory assays to set the path for further diagnosis and research in the field of mitochondrial diseases., This work was supported by Instituto de Salud Carlos III (ISCIII), grants FIS PI17/00021, PI17/00359, PI18/00498, PI18/00451, PI18/01374, PI19/01772, PI20/00541, PI21/00229, PI21/00381 and PI21/00935 (ISCIII-FEDER “Cofinanciado por la Unión Europea”), Fundació Privada Cellex, Junta de Andalucía (UPO-1262247) and Ministerio de Ciencia e Innovación (MCINN) grant PID2019-110320RBI00. All participant centers are integrated in the Centro de Investigación Biomédica en Red (CIBER), Sección de Enfermedades Raras (CIBERER, an initiative of ISCIII), which is the founder of this present methodological study.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Targeting cancer stem cell OXPHOS with tailored ruthenium complexes as a new anti-cancer strategy

  • Alcalá, Sonia
  • Villarino, Lara
  • Ruiz-Cañas, Laura
  • Couceiro, José R.
  • Martínez‑Calvo, Miguel
  • Palencia-Campos, Adrián
  • Navarro, Diego
  • Cabezas-Sainz, Pablo
  • Rodríguez‑Arabaolaza, Iker
  • Cordero‑Barreal, Alfonso
  • Trilla-Fuertes, Lucía
  • Rubiolo, Juan A.
  • Batres-Ramos, Sandra
  • Vallespinós, Mireia
  • González‑Páramos, Cristina
  • Rodríguez, Jéssica
  • Gámez, Ángelo
  • Fresno Vara, Juan Ángel
  • Fra Fernández, Sara
  • Benito Berlinches, Amparo
  • Moreno‑Mata, Nicolás
  • Torres Redondo, Ana María
  • Carrato, Alfredo
  • Hermann, Patrick C.
  • Sánchez, Laura
  • Torrente, Susana
  • Fernández‑Moreno, Miguel Ángel
  • Mascareñas, José L.
  • Sainz, Bruno Jr.
[Background]: Previous studies by our group have shown that oxidative phosphorylation (OXPHOS) is the main pathway by which pancreatic cancer stem cells (CSCs) meet their energetic requirements; therefore, OXPHOS represents an Achille’s heel of these highly tumorigenic cells. Unfortunately, therapies that target OXPHOS in CSCs are lacking., [Methods]: The safety and anti-CSC activity of a ruthenium complex featuring bipyridine and terpyridine ligands and one coordination labile position (Ru1) were evaluated across primary pancreatic cancer cultures and in vivo, using 8 patient-derived xenografts (PDXs). RNAseq analysis followed by mitochondria-specific molecular assays were used to determine the mechanism of action., [Results]: We show that Ru1 is capable of inhibiting CSC OXPHOS function in vitro, and more importantly, it presents excellent anti-cancer activity, with low toxicity, across a large panel of human pancreatic PDXs, as well as in colorectal cancer and osteosarcoma PDXs. Mechanistic studies suggest that this activity stems from Ru1 binding to the D-loop region of the mitochondrial DNA of CSCs, inhibiting OXPHOS complex-associated transcription, leading to reduced mitochondrial oxygen consumption, membrane potential, and ATP production, all of which are necessary for CSCs, which heavily depend on mitochondrial respiration., [Conclusions]: Overall, the coordination complex Ru1 represents not only an exciting new anti-cancer agent, but also a molecular tool to dissect the role of OXPHOS in CSCs. Results indicating that the compound is safe, non-toxic and highly effective in vivo are extremely exciting, and have allowed us to uncover unprecedented mechanistic possibilities to fight different cancer types based on targeting CSC OXPHOS., This study was supported by a Fero Foundation Grant (B.S.,Jr.); Rámon y Cajal Merit Award (RYC-2012-12104) from the Ministerio de Economía y Competitividad, Spain (B.S.,Jr.); funding from the Beca Carmen Delgado/Miguel Pérez-Mateo from AESPANC-ACANPAN Spain (B.S.,Jr.); a Conquer Cancer Now Grant from the Concern Foundation (Los Angeles, CA, USA) (B.S.,Jr.); a Coordinated grant (GC16173694BARB; B.S.,Jr.) and SEED grant (IDEAS222917FERN; M.A.F.-M.) from the Fundación Asociación Española Contra el Cáncer (AECC); FIS grants PI18/00757 and PI21/01110 (B.S.,Jr.) and PT20/00045 (A.M.T.R and B.S.,Jr.), (co-financed through Fondo Europeo de Desarrollo Regional (FEDER) “Una manera de hacer Europa”); an IGNICIA proof of concept grant (IN855A-2018/16) “RuCSC - targeting cancer stem cells using ruthenium compounds”, an initiative of the Agencia Gallega de Innovación (GAIN) to facilitate the access of I+D+i projects to the market (J.L.M and B.S.,Jr.), a La Caixa Research Consolidate grant (CC21-20122; J.L.M and B.S.,Jr.); Spanish national grants PID2019-110320RB-I00 (M.A.F.-M.) from the Ministerio de Ciencia e Innovación (MCIN), IJC2019-040358-I funded by MCIN/AEI/10.13039/501100011033 (J.R.), PID2019-108624RB-I00, PDC2021-121508-I00, PID2022-137318OB-I00 and ORFEO-CINQA network RED2018-102387-T (J.L.M.), the Consellería de Cultura, Educación e Ordenación Universitaria 2015-CP082, IN855A 2018/16, ED431C-2021/25 and Centro Singular de Investigación de Galicia accreditation 2019-2022: ED431G 2019/03 (J.L.M.), the European Union (European Regional Development Fund-ERDF corresponding to the multiannual financial framework 2014-2020), and the European Research Council Advanced Grant No. 340055, Proof-of-concept Grant No. 899334 (J.L.M.). a Max Eder Fellowship of the German Cancer Aid (111746) (P.C.H.); the German Research Foundation (DFG, CRC 1279 “Exploiting the human peptidome for Novel Antimicrobial and Anticancer Agents”) (P.C.H.)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Molecular pathways in mitochondrial disorders due to a defective mitochondrial protein synthesis

  • Antolínez-Fernández, Álvaro
  • Esteban-Ramos, Paula
  • Fernández-Moreno, Miguel Ángel
  • Clemente, Paula
Mitochondria play a central role in cellular metabolism producing the necessary ATP through oxidative phosphorylation. As a remnant of their prokaryotic past, mitochondria contain their own genome, which encodes 13 subunits of the oxidative phosphorylation system, as well as the tRNAs and rRNAs necessary for their translation in the organelle. Mitochondrial protein synthesis depends on the import of a vast array of nuclear-encoded proteins including the mitochondrial ribosome protein components, translation factors, aminoacyl-tRNA synthetases or assembly factors among others. Cryo-EM studies have improved our understanding of the composition of the mitochondrial ribosome and the factors required for mitochondrial protein synthesis and the advances in next-generation sequencing techniques have allowed for the identification of a growing number of genes involved in mitochondrial pathologies with a defective translation. These disorders are often multisystemic, affecting those tissues with a higher energy demand, and often present with neurodegenerative phenotypes. In this article, we review the known proteins required for mitochondrial translation, the disorders that derive from a defective mitochondrial protein synthesis and the animal models that have been established for their study., The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. PC is funded by grant RYC2022-037640-I funded by MICIU/AEI/10.13039/501100011033 and by “ESF investing in your future”. MF-M is funded by grants PID2019-110320RB-I0 funded by Ministerio de Ciencia e Innovación (MICINN), and IDEAS222917FERN funded by Asociación Española Contra el Cáncer-AECC, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Dysfunction of Drosophila mitochondrial carrier homolog (Mtch) alters apoptosis and disturbs development

  • Gónzalez, Cristina
  • Martínez Sánchez, Lidia
  • Clemente, Paula
  • Markus Tolvonen, Janne
  • Arredondo, Juan J.
  • Fernández-Moreno, Miguel Ángel
  • Carrodeguas, José A.
Mitochondrial carrier homologs 1 (MTCH1) and 2 (MTCH2) are orphan members of the mitochondrial transporter family SLC25. Human MTCH1 is also known as presenilin 1-associated protein, PSAP. MTCH2 is a receptor for tBid and is related to lipid metabolism. Both proteins have been recently described as protein insertases of the outer mitochondrial membrane. We have depleted Mtch in Drosophila and show here that mutant flies are unable to complete development, showing an excess of apoptosis during pupation; this observation was confirmed by RNAi in Schneider cells. These findings are contrary to what has been described in humans. We discuss the implications in view of recent reports concerning the function of these proteins., MT was supported by the Government of Spain (RYC-2011-08363). This work was supported by Grant of the Ministerio de Ciencia e Innovación, government of Spain (PID2019-110320RB-I00) to MAF-M; and by BFU2009-11800 (MICINN, Spain) and UZ2010-BIO-03 (Universidad de Zaragoza, Spain) to JAC., Peer reviewed
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Multicentric standardization of protocols for the diagnosis of human mitochondrial respiratory chain defects

  • Bujan, N.
  • Morén, C.
  • García-García, F. J.
  • Blázquez, A.
  • Carnicer, C.
  • Cortés, A. B.
  • González, C.
  • López-Gallardo, E.
  • Lozano, E.
  • Moliner, S.
  • Gort, L.
  • Tobías, E.
  • Delmiro, A.
  • Martin, M. Á.
  • Fernández-Moreno, M. Á.
  • Ruiz-Pesini, E.
  • Garcia-Arumí, E.
  • Rodríguez-Aguilera, J. C.
  • Garrabou, G.
The quantification of mitochondrial respiratory chain (MRC) enzymatic activities is essential for diagnosis of a wide range of mitochondrial diseases, ranging from inherited defects to secondary dysfunctions. MRC lesion is frequently linked to extended cell damage through the generation of proton leak or oxidative stress, threatening organ viability and patient health. However, the intrinsic challenge of a methodological setup and the high variability in measuring MRC enzymatic activities represents a major obstacle for comparative analysis amongst institutions. To improve experimental and statistical robustness, seven Spanish centers with extensive experience in mitochondrial research and diagnosis joined to standardize common protocols for spectrophotometric MRC enzymatic measurements using minimum amounts of sample. Herein, we present the detailed protocols, reference ranges, tips and troubleshooting methods for experimental and analytical setups in different sample preparations and tissues that will allow an international standardization of common protocols for the diagnosis of MRC defects. Methodological standardization is a crucial step to obtain comparable reference ranges and international standards for laboratory assays to set the path for further diagnosis and research in the field of mitochondrial diseases. © 2022 by the authors. Licensee MDPI, Basel, Switzerland.